NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

Sutro Biopharma sets $5.18 share price for stock offering

EditorEmilio Ghigini
Published 04/02/2024, 06:27 AM
STRO
-

SOUTH SAN FRANCISCO - Sutro Biopharma , Inc. (NASDAQ: NASDAQ:STRO), a clinical-stage company specializing in antibody drug conjugates (ADCs) for oncology, has announced the pricing of its public offering.

The company will offer 14,478,764 shares of common stock at $5.18 per share, expecting to raise approximately $75 million before fees and expenses. The offering, led by healthcare-focused institutional investors, is anticipated to close on April 4, 2024, pending customary closing conditions.

Sutro's current financial strategy includes utilizing the net proceeds alongside existing capital for various corporate endeavors. These include but are not limited to research, clinical and process development, manufacturing of product candidates, working capital, commercialization infrastructure, and potential business acquisitions or investments.

BofA Securities is the sole book-running manager for the offering, which is being made under a previously filed SEC registration statement. The prospectus and accompanying supplement detailing the offering terms will be available on the SEC's website.

Sutro Biopharma, headquartered in South San Francisco, focuses on developing precise cancer therapeutics. Its technology, including the cell-free XpressCF®, aims to benefit a broader patient demographic and enhance the patient experience. The company has several clinical stage candidates, including luveltamab tazevibulin (luvelta), a FolRα-targeting ADC currently in registrational-stage clinical studies.

The company's forward-looking statements involve risks and uncertainties, including market conditions, the completion of the offering, and the anticipated use of proceeds. These statements reflect Sutro's expectations as of the date of this release and are subject to change. The company assumes no obligation to update any forward-looking statements after the date of this release.

InvestingPro Insights

As Sutro Biopharma gears up for its public offering, investors are keenly observing the company's financial health and market performance. According to real-time data from InvestingPro, Sutro Biopharma's market capitalization stands at a modest $332.5 million. This reflects the company's position as a clinical-stage entity within the competitive biopharma sector.

InvestingPro Data reveals a significant revenue growth of 126.84% for the last twelve months as of Q4 2023, indicating a strong upward trajectory in sales. This is further underscored by a quarterly revenue growth of 1217.44% for Q4 2023, suggesting a robust short-term performance.

Despite these impressive growth figures, Sutro Biopharma's financials also show challenges. The company's gross profit margin was reported at -17.36% for the same period, which aligns with the InvestingPro Tip that the company suffers from weak gross profit margins. Additionally, the negative P/E ratio of -2.89 points to earnings difficulties, which is consistent with the InvestingPro Tip that analysts do not anticipate the company will be profitable this year.

On the investment front, Sutro Biopharma has seen a strong return over the last six months, with a price total return of 52.14%. This could signal investor confidence in the company's long-term strategy and pipeline potential.

For those considering deeper investment analysis, InvestingPro offers additional insights. There are 11 more InvestingPro Tips available that could help investors understand the nuances of Sutro Biopharma's financial and market position. These tips can be accessed through the InvestingPro platform at https://www.investing.com/pro/STRO.

Investors interested in leveraging these insights can take advantage of an exclusive offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. This offer could provide valuable information for making informed decisions in a volatile and ever-evolving market like biopharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.